Clene Inc. (CLNN)

NASDAQ: CLNN · IEX Real-Time Price · USD
4.620
-0.180 (-3.75%)
Jul 19, 2024, 11:47 AM EDT - Market open
-3.75%
Market Cap 30.05M
Revenue (ttm) 620,000
Net Income (ttm) -48.81M
Shares Out 6.44M
EPS (ttm) -9.20
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 19,830
Open 4.840
Previous Close 4.800
Day's Range 4.620 - 4.920
52-Week Range 4.590 - 16.200
Beta 0.46
Analysts Strong Buy
Price Target 6.50 (+40.69%)
Earnings Date Aug 12, 2024

About CLNN

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 ... [Read more]

Industry Packaged Foods
Founded 2012
Employees 85
Stock Exchange NASDAQ
Ticker Symbol CLNN
Full Company Profile

Financial Performance

In 2023, Clene's revenue was $654,000, an increase of 38.27% compared to the previous year's $473,000. Losses were -$49.50 million, 65.5% more than in 2022.

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for CLNN stock is "Strong Buy." The 12-month stock price forecast is $6.5, which is an increase of 40.69% from the latest price.

Price Target
$6.5
(40.69% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Clene to Present at the Emerging Growth Conference

SALT LAKE CITY, July 12, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmace...

7 days ago - GlobeNewsWire

Clene Announces Plans to Submit Briefing Book to the U.S. Food and Drug Administration in Connection with Granted Type C Interaction to Obtain FDA Feedback on Potential Pathway to Accelerated Approval for CNM-Au8® in ALS

SALT LAKE CITY, July 11, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmace...

8 days ago - GlobeNewsWire

Clene Announces 1-for-20 Reverse Stock Split

SALT LAKE CITY, July 09, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmace...

10 days ago - GlobeNewsWire

Clene to Present at H.C. Wainwright's 5th Annual Neuro Perspectives Virtual Conference

SALT LAKE CITY, June 24, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmace...

25 days ago - GlobeNewsWire

Clene Presents Preliminary Data for CNM-Au8® as a Potential Treatment for Rett Syndrome

SALT LAKE CITY, June 21, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly-owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmace...

4 weeks ago - GlobeNewsWire

Clene Presents Extended Survival Data Through 3.5 Years and New NfL Responder Results with CNM-Au8® 30 mg Treatment from the HEALEY ALS Platform Trial Open Label Extension at the 2024 ENCALS Meeting

SALT LAKE CITY, June 18, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmace...

4 weeks ago - GlobeNewsWire

Clene Provides Update on Its NIH-Funded Expanded Access Program for CNM-Au8® in ALS (ACT-EAP)

SALT LAKE CITY, May 28, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly-owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceu...

7 weeks ago - GlobeNewsWire

Clene to Present at Upcoming May Conferences

SALT LAKE CITY, May 14, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biophar...

2 months ago - GlobeNewsWire

Clene Reports First Quarter 2024 Financial Results and Recent Operating Highlights

SALT LAKE CITY, May 08, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a late clinical-stage biopha...

2 months ago - GlobeNewsWire

Evidence for Clene's CNM-Au8® as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual Meeting

SALT LAKE CITY, April 16, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharma...

3 months ago - GlobeNewsWire

Clene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8®

SALT LAKE CITY, March 15, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmac...

4 months ago - GlobeNewsWire

Clene Reports Full Year 2023 Financial Results and Recent Operating Highlights

SALT LAKE CITY, March 13, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmac...

4 months ago - GlobeNewsWire

Clene Presents Clinical Results of CNM-Au8® 30mg Treatment From Visionary-MS Trial Long-Term Extension at Annual ACTRIMS Forum 2024

SALT LAKE CITY, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmace...

5 months ago - GlobeNewsWire

Clene says FDA finds ALS drug data not enough for accelerated nod

Dec 21 (Reuters) - Clene (CLNN.O) said on Thursday data on its therapy to treat a type of neurological disease did not meet the U.S. drug regulator's target for accelerated approval.

7 months ago - Reuters

Clene Reports Reduction in Biomarker Plasma Neurofilament Light (NfL) Levels and Improved Survival With CNM-Au8® Treatment From HEALEY ALS Platform Trial Long-Term Open Label Extension

SALT LAKE CITY, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmace...

7 months ago - GlobeNewsWire

Clene Provides Update on ALS Clinical Development Meeting With FDA

SALT LAKE CITY, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmace...

7 months ago - GlobeNewsWire

Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Brain Target Engagement In Neurodegenerative Diseases

SALT LAKE CITY, Dec. 14, 2023 (GLOBE NEWSWIRE) --  Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage bioph...

7 months ago - GlobeNewsWire

Clene Reports Third Quarter 2023 Financial Results and Operating Highlights

SALT LAKE CITY, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopha...

9 months ago - GlobeNewsWire

National Institutes of Health Awards $45.1 Million NINDS Grant for CNM-Au8® Study in ALS

Funding to Support Research and Expanded Access of Investigational Drug in ALS Funding to Support Research and Expanded Access of Investigational Drug in ALS

10 months ago - GlobeNewsWire

Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Catalytic Neuroprotective Mechanism of Action

Novel catalytic mechanism of CNM-Au8 reveals its promise as a versatile new treatment to address multiple assaults on neuronal health in neurodegenerative diseases

10 months ago - GlobeNewsWire

Clene to Present at Cantor Fitzgerald Annual Global Healthcare Conference

SALT LAKE CITY, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage bioph...

10 months ago - GlobeNewsWire

Clene Reports Significant Long-Term Survival Improvement From CNM-Au8 Treatment in HEALEY ALS Platform Trial Compared to PRO-ACT Historical Controls

SALT LAKE CITY, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) through its wholly owned subsidiary Clene Nanomedicine, Inc. (collectively “Clene”), today announced long-term follow-up da...

10 months ago - GlobeNewsWire

Clene to Present at Upcoming September Conferences

SALT LAKE CITY, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopha...

11 months ago - GlobeNewsWire

Clene Reports Significantly Improved Survival Benefit of 19.3 Months and Significantly Delayed Clinical Worsening in Rescue-Als Open-Label Extension Two Year Follow-Up

SALT LAKE CITY, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) through its wholly owned subsidiary Clene Nanomedicine Inc., today announced the 24-month long-term data cut from the Phase ...

11 months ago - GlobeNewsWire

Clene Reports Second Quarter 2023 Financial Results and Operating Highlights

SALT LAKE CITY, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopha...

1 year ago - GlobeNewsWire